Skip to content
Login
Search:
CROI Conference
CROI ConferenceCROI Conference
  • About CROI
    • CROI 2027 Important Dates
    • CROI Foundation
    • Scientific Program Committee and Community Liaison Subcommittee
    • Funding and Grant Support
    • IAS-USA
    • Policies, Website, and Copyrights
    • Illustrations of HIV, HCV, and SARS-CoV-2 Viruses
    • Contact Us
  • Abstracts
    • CROI Abstract Categories
    • Abstract Guidelines and Submission
    • Assignment of Abstract Copyright to CROI
    • People-First Language and the Use of Appropriate Terminology
  • Presenters
    • Invited Presenters and Moderators
    • Letter Of Invitation (For Visa And Other Purposes)
  • Attendees
    • Who Can Attend
    • Letter Of Invitation (For Visa And Other Purposes)
    • Affiliated and Proximate Activities
    • Frequently Asked Questions
  • Scholarships
    • New Researcher Scholarship
    • International Researcher Scholarship
    • Community Educator and Mentor Scholarships
  • Program
    • CROI 2027 Program
    • Our Voices
    • Media
    • Embargo Policies And Press Release Policies
    • Resources From Prior Years
    • Webcasts
    • Abstracts and ePoster Archive
    • CROI Issues of TAM
  • About CROI
    • CROI 2026 Preliminary Important Dates and Deadlines
    • CROI Foundation
    • Scientific Program Committee and Community Liaison Subcommittee
    • Funding and Grant Support
    • IAS-USA
    • Policies, Website, and Copyrights
    • Illustrations of HIV, HCV, and SARS-CoV-2 Viruses
    • Contact Us
  • Abstracts
    • Abstract Guidelines and Submission
    • CROI Abstract Categories
    • Assignment of Abstract Copyright to CROI
    • People-First Language and the Use of Appropriate Terminology
  • Presenters
    • Invited Presenters and Moderators
    • Oral Abstract Presentation Guidelines
    • Poster Presentation Guidelines
    • Themed Discussion Guidelines
    • Plain Language Summaries: A Mile-High View at CROI 2026
    • People-First Language and the Use of Appropriate Terminology
    • Letter Of Invitation (For Visa And Other Purposes)
  • Attendees
    • Registration
    • Who Can Attend
    • Media Accreditation and Registration
    • Affiliated and Proximate Activities
    • Frequently Asked Questions
  • Scholarships
    • New Researcher Scholarship
    • International Researcher Scholarship
    • Community Educator and Mentor Scholarships
    • Scholarship Travel
  • Program
    • CROI 2027 Program
    • CROI 2026 Resources
    • Our Voices
    • Media
    • Resources From Prior Years
    • Webcasts
    • Abstracts and ePoster Archive
    • CROI Issues of TAM
  • CROI 2027 Important Dates

Search Results for: node/PEP: Remember Me?

Identification of Novel B*57:01 Restricted Peptides From HIV gp140 Using Immunopeptidomics

By Enthusiast Inc MDSeptember 29, 2014

…assignments were rigorously curated and validated with isotopically labeled HIV peptides. Results: Over 2900 B*57:01-restricted human peptides were identified and we confirmed ten B*57:01 restricted, naturally presented HIV-gp140 peptides using…

1275 – Post-Exposure Prophylaxis With Doxycycline (Doxy PEP) in a Cohort of High-Risk MSM: The PRIDOX Study

By Jimmy He PharmD, DScMarch 18, 2025

…DoxyPEP trials, were offered DoxyPEP. This analysis includes PrEP users who initiated DoxyPEP between March/23 and August/24. The pre-DoxyPEP period was from PrEP initiation to DoxyPEP beginning, and the post-DoxyPEP…

1284 – Antimicrobial Consumption Among Users of Doxycycline Postexposure Prophylaxis in Milan, Italy

By Jimmy He PharmD, DScMarch 20, 2025

…prophylaxis (DoxyPEP) among men who have sex with men (MSM). Methods Retrospective study of MSM in care for HIV or HIV pre-exposure prophylaxis (PrEP) at the Infectious Diseases Unit of…

162 – DoxyPEP Eligibility, Use, and Potential for STI Reduction in a Large HIV Cohort in Washington, DC

By Jimmy He PharmD, DScMarch 20, 2025

…cohort of PWH in Washington, DC.  Methods DC Cohort longitudinal HIV cohort participants were considered DoxyPEP eligible per the CDC guidelines if they were men who have sex with men…

544 – Latency Reversal Induced by CD4+ T-Cell Recognition of HIV-1 Alternate Reading Frame Proteins

By Jimmy He PharmD, DScMarch 20, 2025

…CD4+ T cells in chronic progressors (CPs) would recognize ARFP peptides and that these peptides could be used to reverse latency. Methods We performed a 10-day expansion assay using CD8+…

Darunavir(DRV)/r-Based PEP Versus Standard of Care (SOC) – the Randomized PEPDar Study

By Enthusiast Inc MDSeptember 29, 2014

…to currently used drugs (mainly lopinavir (LPV)/r). This study was designed to generate data on safety and tolerability of DRV/r-based PEP compared to SOC-PEP. Methodology: PEPDar was an open-label, randomized…

Modulation of Natural Killer Cell Activity by Simian Immunodeficiency Virus Peptides

By Enthusiast Inc MDSeptember 29, 2014

…but not by others. Methodology: Using an A1*002-expressing, transporter associated with antigen processing (TAP)-inhibited cell line pulsed with individual peptides, we evaluated 75 SIV peptides previously shown to bind to…

998 – BIC/FTC/TAF for PEP: Completion, Tolerability, and Transition to PrEP in a Real-World Cohort

By Jimmy He PharmD, DScApril 1, 2026

…to ED in the study period, and PEP with BIC/FTC/TAF was started in 381. Among them, PEP was confirmed in 273 persons after reassessment in the dedicated service. Demographic and…

Contingency Management Facilitates PEP Completion Among Stimulant-Using MSM

By Enthusiast Inc MDSeptember 29, 2014

…previously reported that in a single-arm pilot intervention of PEP combined with CM in methamphetamine-using MSM, time to PEP initiation, adherence, and course completion rates were not different from historical…

POSTEXPOSURE PROPHYLAXIS AND HIV RISK IN RWANDA: POTENTIAL FOR PEP-TO-PrEP PROGRAMS

By Enthusiast Inc MDMarch 7, 2019

…disproportionately seek PEP more often than men, often in response to gender-based violence and/or sexual assault. In addition, anecdotal evidence suggests some persons seek PEP repeatedly, and may be discouraged…

←12345…
678910111213141516171819202122232425262728293031323334353637383940414243444546474849505152535455565758596061626364656667686970717273747576777879808182
83→
Copyright © 2026 CROI Foundation/IAS-USA. All Rights Reserved.
Website by Enthusiast, Inc.
  • About CROI
  • Presenters
  • Abstracts
  • Scholarships
  • Program
Footer Menu
Go to Top